Grant: Project Grant
McGill University
$100,000.00
Investigation of amyloid seeding in Cerebral Amyloid Angiopathy
FY 2022-23
Summary
To date, Alzheimer disease (AD) research has primarily focused on conversion of the amyloid precursor protein into the aggregation prone amyloid-beta 42 (Abeta42) peptide which can stick together to form amyloid plaques in the brain. Clinically, the ratio between non-aggregating Abeta40 and aggregating Abeta42 peptides indicates whether the stage of disease progression is mild, moderate, or severe (i.e. level of Abeta42 decreases in patient body fluids as it becomes deposited as plaques).
Distinct from the Abeta42 imbalances in AD patients, we have preliminary evidence suggesting that the atypical aggregation of Abeta40 may contribute to the development of cerebral amyloid angiopathy (CAA). CAA is a neurological disease in which Abeta40 binds to blood vessels, prompting memory problems and strokes due to bleeding in the brain. Recent studies suggest that CAA and AD are caused by decreased Abeta clearance which leads to increased deposition of amyloid plaques.
To better understand the dynamic balance between the production and clearance of Abeta peptides in the genesis of both sporadic and inherited forms of CAA, our project will examine the role of specific amyloid peptides in CAA-relevant human cells and tissues. Ultimately, understanding the distinct molecular mechanisms that govern amyloid peptide aggregation in CAA and AD will lead to the future development of novel, disease-specific prevention strategies.
Department
Program
Project Grant
Recipient
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
477296
Name
Multhaup Gerhard
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Aging
Theme2
Biomedical
Prcname2
Cell Biology - Disease
Projecttitle
Investigation of amyloid seeding in Cerebral Amyloid Angiopathy
Programtype2
Operating Grants
Orgnameinp2
McGill University
Cihramount2
$100,000
Cihrequipment2
$0
Programname2
Project Grant
Keyworddelim
Abeta Aggregation; Alzheimer Disease; Amyloid Clearance; Animal Models; Cerebral Amyloid Angiopathy; Human Cells And Tissues; Seeding/Template
Abstract
To date, Alzheimer disease (AD) research has primarily focused on conversion of the amyloid precursor protein into the aggregation prone amyloid-beta 42 (Abeta42) peptide which can stick together to form amyloid plaques in the brain. Clinically, the ratio between non-aggregating Abeta40 and aggregating Abeta42 peptides indicates whether the stage of disease progression is mild, moderate, or severe (i.e. level of Abeta42 decreases in patient body fluids as it becomes deposited as plaques).
Distinct from the Abeta42 imbalances in AD patients, we have preliminary evidence suggesting that the atypical aggregation of Abeta40 may contribute to the development of cerebral amyloid angiopathy (CAA). CAA is a neurological disease in which Abeta40 binds to blood vessels, prompting memory problems and strokes due to bleeding in the brain. Recent studies suggest that CAA and AD are caused by decreased Abeta clearance which leads to increased deposition of amyloid plaques.
To better understand the dynamic balance between the production and clearance of Abeta peptides in the genesis of both sporadic and inherited forms of CAA, our project will examine the role of specific amyloid peptides in CAA-relevant human cells and tissues. Ultimately, understanding the distinct molecular mechanisms that govern amyloid peptide aggregation in CAA and AD will lead to the future development of novel, disease-specific prevention strategies.
Competitiondate
202210
Approvedterm2
1 yr 0 mth
Pinamesdelim
Multhaup, Gerhard
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $100,000~ $0~